FDA's Makary Resigns With Agency in Turmoil
Speakers
Rachel Cohrs Zhang
— Bloomberg health policy reporter
Summary
FDA Commissioner Marty Makary resigns after 13 months amid policy disagreements and management clashes. Kyle Diamantas takes over as acting commissioner, viewed as a steady hand. Biotech shares reacted to the departure, but the reporter notes this reflects dissatisfaction with Makary rather than optimism about future leadership.
- FDA Commissioner Marty Makary resigns after 13 months.
- Kyle Diamantas named acting commissioner, seen as a steady hand.
- Makary's departure stems from policy disputes and management clashes.
- Biotech shares saw a bump, attributed to Makary leaving, not future outlook.
- Search for a permanent commissioner through Senate confirmation continues.
